Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
8
pubmed:dateCreated
2008-9-24
pubmed:abstractText
Therapeutic dendritic cell (DC) vaccination against cancer is a strategy aimed at activating the immune system to recognize and destroy tumor cells. In this nonrandomized phase 1/2 trial, we investigated the safety, feasibility, induction of T-cell response, and clinical response after treatment with a DC-based vaccine in patients with metastatic renal cell carcinoma. Twenty-seven patients with progressive cytokine-refractory metastatic renal cell carcinoma were vaccinated with DCs loaded with either a cocktail of survivin and telomerase peptides or tumor lysate depending on their HLA-A2 haplotype, and low-dose IL-2 was administered concomitantly. Tumor response, immune response, and serum IL-6 and YKL-40 were measured during treatment. Vaccine generation was successful in all patients and no serious adverse events were observed. None of the patients had an objective response but 13/27 patients obtained disease stabilization (SD) for more than 8 weeks. An antigen-specific immune response was demonstrated in 6/6 patients tested. Furthermore, significant alterations in serum YKL-40 and IL-6 were found during treatment. In conclusion, DC vaccination in our setting is feasible and without severe toxicity. Almost half of the patients obtained SD, and in more than 1/3 of the patients, SD persisted for more than 6 months. However, the evaluation of SD is difficult to interpret in the absence of a randomized trial and, therefore, these results should be interpreted with caution. Antigen-specific immune responses were observed in a subset of the treated patients.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
http://linkedlifedata.com/resource/pubmed/chemical/Adipokines, http://linkedlifedata.com/resource/pubmed/chemical/BIRC5 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/CHI3L1 protein, human, http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines, http://linkedlifedata.com/resource/pubmed/chemical/Glycoproteins, http://linkedlifedata.com/resource/pubmed/chemical/Inhibitor of Apoptosis Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-2, http://linkedlifedata.com/resource/pubmed/chemical/Interleukin-6, http://linkedlifedata.com/resource/pubmed/chemical/Lectins, http://linkedlifedata.com/resource/pubmed/chemical/Microtubule-Associated Proteins, http://linkedlifedata.com/resource/pubmed/chemical/Peptides, http://linkedlifedata.com/resource/pubmed/chemical/Telomerase
pubmed:status
MEDLINE
pubmed:month
Oct
pubmed:issn
1537-4513
pubmed:author
pubmed:issnType
Electronic
pubmed:volume
31
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
771-80
pubmed:dateRevised
2011-11-17
pubmed:meshHeading
pubmed-meshheading:18779742-Adipokines, pubmed-meshheading:18779742-Adult, pubmed-meshheading:18779742-Aged, pubmed-meshheading:18779742-Amino Acid Sequence, pubmed-meshheading:18779742-Cancer Vaccines, pubmed-meshheading:18779742-Carcinoma, Renal Cell, pubmed-meshheading:18779742-Cell Line, Tumor, pubmed-meshheading:18779742-Dendritic Cells, pubmed-meshheading:18779742-Female, pubmed-meshheading:18779742-Glycoproteins, pubmed-meshheading:18779742-Humans, pubmed-meshheading:18779742-Immunotherapy, Adoptive, pubmed-meshheading:18779742-Inhibitor of Apoptosis Proteins, pubmed-meshheading:18779742-Interleukin-2, pubmed-meshheading:18779742-Interleukin-6, pubmed-meshheading:18779742-Kaplan-Meier Estimate, pubmed-meshheading:18779742-Kidney Neoplasms, pubmed-meshheading:18779742-Lectins, pubmed-meshheading:18779742-Male, pubmed-meshheading:18779742-Microtubule-Associated Proteins, pubmed-meshheading:18779742-Middle Aged, pubmed-meshheading:18779742-Molecular Sequence Data, pubmed-meshheading:18779742-Peptides, pubmed-meshheading:18779742-T-Lymphocytes, Cytotoxic, pubmed-meshheading:18779742-Telomerase, pubmed-meshheading:18779742-Vaccination
pubmed:year
2008
pubmed:articleTitle
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma: a clinical phase 1/2 trial.
pubmed:affiliation
Department of Oncology section, Center for Cancer Immunotherapy, Herlev Hospital, Herlev, Denmark.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Clinical Trial, Phase II, Clinical Trial, Phase I